<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> are a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of acquired primary and secondary alterations of hematopoietic stem cells that result in cytopenias in blood and cytologic features of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in blood and/or bone marrow </plain></SENT>
<SENT sid="1" pm="."><plain>To better understand the cytologic features that would permit differentiation of primary and secondary forms of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, we reviewed 267 consecutive bone marrow reports from dogs </plain></SENT>
<SENT sid="2" pm="."><plain>These reports indicated that 34 dogs (12.7%) had dysgranulopoiesis, dyserythropoiesis, and/or dysthrombopoiesis in &gt;10% of granulopoietic cells, erythroid cells, and/or megakaryocytes, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Thirteen dogs had primary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, and 21 had secondary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Of the 13 dogs with primary <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, 4 were subclassified as <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA), and 9 were subclassified as <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-EB) </plain></SENT>
<SENT sid="5" pm="."><plain>Secondary conditions associated with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in the bone marrow included malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 5), <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (n = 3), immune-mediated <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (n = 4), immune-mediated <z:hpo ids='HP_0001878'>hemolytic anemia</z:hpo> (n = 5), <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> with melphalan administration (n = 1), <z:mpath ids='MPATH_693'>pyometra</z:mpath> with <z:chebi fb="0" ids="50114">estrogen</z:chebi> administration (n = 1), <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (n = 1), and thrombopathia (n = 1) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA was characterized by &lt;5% myeloblasts in bone marrow, <z:mpath ids='MPATH_458'>normal</z:mpath> granulocyte maturation ratio, increased erythroid maturation ratio, and dysplastic changes in &gt;15% of erythroid cells </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e>-EB was characterized by &gt;/=5% myeloblasts in bone marrow, high granulocyte maturation and erythroid maturation ratios, &gt;/=32% dysplastic granulocytes, and the presence of small atypical immature myeloid cells </plain></SENT>
<SENT sid="8" pm="."><plain>Secondary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> were characterized by &lt;5% myeloblasts in bone marrow, variable granulocyte maturation and erythroid maturation ratios, and variable dysplastic features </plain></SENT>
<SENT sid="9" pm="."><plain>These results indicate that <z:mp ids='MP_0000002'>morphology</z:mp> alone cannot be used to distinguish primary and secondary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> in dogs </plain></SENT>
</text></document>